# A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

> **NCT05488314** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 57 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Capmatinib
- **DRUG:** Amivantamab

## Key facts

- **NCT ID:** NCT05488314
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-13
- **Primary completion:** 2026-06-09
- **Final completion:** 2027-04-28
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05488314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05488314, "A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT05488314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*